share_log

Jefferies Downgrades Beam Therapeutics to Hold, Lowers Price Target to $30

Benzinga ·  Dec 8, 2023 06:56

Jefferies analyst Michael Yee downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Hold and lowers the price target from $75 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment